FHTX · XBRL financial data

Foghorn Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FHTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	430	1,319	19,228	34,155	22,602	30,909
Research and development	57,715	80,325	105,618	109,689	94,528	85,466
General and administrative	11,246	21,728	30,747	32,372	28,359	27,550
Total operating expenses	68,961	102,053	136,365	142,061	125,285	117,298
Operating income (loss)	(68,531)	(100,734)	(117,137)	(107,906)	(102,683)	(86,389)
Interest expense	979	1,906	—	—	—	—
Other income (expense)	—	2,494	2,580	—	—	—
Income tax expense (benefit)	0	—	0	4,226	0	0
Net income (loss)	(68,800)	(101,320)	(108,882)	(98,426)	(86,620)	(74,283)
Earnings per share, basic USD per share	(6.23)	(2.73)	(2.62)	(2.34)	(1.58)	(1.18)
Earnings per share, diluted USD per share	(6.23)	(2.73)	(2.62)	(2.34)	(1.58)	(1.18)
Weighted average shares, basic thousands of shares	11,047	37,171	41,591	41,974	54,899	62,981
Weighted average shares, diluted thousands of shares	11,047	37,171	41,591	41,974	54,899	62,981

Fiscal years (FHTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	92,795	101,136	52,214	80,336	55,454	80,876
Prepaid and other current assets	4,917	5,273	5,601	6,124	5,854	3,091
Total current assets	190,687	459,562	351,399	240,181	249,601	163,235
Property and equipment, net	19,528	—	—	—	—	—
Right-of-use asset	42,804	38,516	34,086	29,956	22,641	30,949
Total assets	255,594	519,774	404,883	285,916	283,982	198,103
Accounts payable	3,680	3,819	5,414	6,260	3,785	4,266
Accrued liabilities	9,161	9,562	11,001	9,108	8,531	11,357
Current portion of long-term debt	0	—	—	—	—	—
Total current liabilities	18,846	48,692	55,205	58,436	66,989	59,738
Long-term debt	19,654	0	—	—	—	—
Lease liability, non-current	58,361	51,338	45,537	36,555	28,064	40,347
Total liabilities	109,407	422,903	404,771	363,106	329,510	306,603
Accumulated deficit	(162,936)	(264,256)	(373,138)	(471,564)	(558,184)	(632,467)
Total stockholders' equity	146,187	96,871	112	(77,190)	(45,528)	(108,500)
Total liabilities and equity	255,594	519,774	404,883	285,916	283,982	198,103
Common shares outstanding (cover page) thousands of shares	36,817	41,422	41,804	42,566	55,612	58,700

Fiscal years (FHTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(68,800)	(101,320)	(108,882)	(98,426)	(86,620)	(74,283)
Stock-based compensation	2,961	8,384	14,336	16,186	11,893	10,399
Depreciation and amortization	1,327	3,227	3,321	3,451	3,120	3,332
Net cash from operating activities	(31,286)	(50,250)	193,612	(118,106)	(100,406)	(86,099)
Purchases of property and equipment	16,183	3,313	1,210	1,224	906	50
Net cash from investing activities	(108,914)	36,173	(244,322)	144,450	(29,904)	112,040
Proceeds from issuing common stock	—	—	—	0	103,401	—
Net cash from financing activities	217,473	22,418	1,763	1,778	105,428	1,023

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Foghorn Therapeutics	68,080	16,072	(17,844)*	59.4M	3.8 quarters	Q2 FY26 10-QJun 30, 2026
Omeros	1,988	28,529	4,149*	72.4M	—	Q2 FY26 10-QJun 30, 2026
Lexicon Pharmaceuticals	44,081	11,250	(8,079)*	445.2M	17.2 quarters	Q3 FY26 10-QSep 30, 2026
XOMA Royalty	85,600	12,318	6,121	12.5M	—	Q1 FY26 10-QMar 31, 2026
Crescent Biopharma	171,593	0	(19,463)*	37.1M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
4D Molecular Therapeutics	70,372	3,781	(69,999)*	55.2M	6.2 quarters	Q2 FY26 10-QJun 30, 2026
Lineage Cell Therapeutics	37,355	1,069	(7,244)*	252.9M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	49,629	not reported	(22,702)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 2:29 PM ET. The filing on SEC.gov is the record.